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Stimulationof HumanMetastaticMelanomaColony-formingCells by an
Acid-sensitiveFactor in HumanPlateletSonicate1
Nancy J. Sipes, Marvin D. Bregman, and Frank L. Meyskens, Jr.2
Cancer Center and Department of Internal Medicine, University of Arizona, Tucson, Arizona 85724
ABSTRACT
A human platelet sonicate was evaluated for its effects on the
growth of human metastatic melanoma colony-forming cells in
soft agar from cells in culture and from biopsies. The addition of
platelet sonicate increased both cloning efficiency and prolifera-
tive capacity in that more and larger colonies were formed. In
more detailed studies under growth-limiting conditions, mela
noma cellular responses to known growth factors were com
pared to the activity found in the platelet sonicate. None of the
growth factors tested either alone or in combination, including
platelet-derived growth factor, epidermal growth factor, a-type
transforming growth factor, and 0-type transforming growth
factor, were capable of inducing melanoma colony formation to
the 12-fold stimulation observed with the platelet sonicate. Treat
ment of platelet sonicate with dithiothreitol, trypsin, or acid
resulted in loss of activity for human melanoma. Our results
suggest that human platelets contain an acid-sensitive protein
which can support the expression of the transformed phenotype
of human melanoma, and this factor is distinct from acid-stable
activities previously characterized from human platelets.
INTRODUCTION
The ability to grow malignant cells in soft agar allows investi
gation of subpopulations of tumor cells, specifically the clono-
genic cells (11). These cells express their proliferative potential
in soft agar by forming colonies under conditions which do not
favor colony formation of normal cells. The cloning of tumor cells
has been used to evaluate responses of tumor cells to chemo-
therapeutic drugs (1, 13, 16, 17, 24) as well as biological modi
fiers (5,12).
Colony formation in soft agar can also be used to investigate
factors which regulate expression of the transformed phenotype.
The demonstration by Todaro ef al. (28) that some tumor cells
release TGFs3 which support reversible anchorage-independent
growth of nontransformed cells suggests that these proteins
may be important for the maintenance of the transformed phe
notype. The subsequent identification by Roberts ef al. (20) of
TGF activity in nonneoplastic tissues suggested that these com
pounds may play a role in normal cell proliferation as well. Serum
contains a platelet-derived TGF-like activity (6); thus in respon
sive cells serum may provide a stimulus for the expression of
the transformed phenotype in soft agar. Colony formation in soft
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agar may represent the ability of the tumor cell to respond to
growth-regulatory molecules provided by serum in the plating
medium; therefore low cloning efficiency may reflect, in part, a
decreased cellular responsiveness or an increased requirement
for such factors.
Tumor cells can proliferate in response to factors contained in
human platelets. Such growth enhancement has been observed
in monolayer culture with cells from various species including
murine and human cell lines (8, 10). Cowan and Graham (7)
examined human platelet effects on soft agar growth of a variety
of human tumor samples, including melanoma. They observed
enhanced colony formation in 47% of their melanoma samples.
We examined in detail the effect of sonicated platelets on cell
cloning of melanoma in soft agar. The biological activity of our
platelet preparation was demonstrated by colony formation of
NRK fibroblasts which were used as nontransformed phenotypic
indicators of TGF activity (3). Cells from four human metastatic
malignant melanoma cell strains, one long-term melanoma cell
line, and four of ten melanoma patient samples responded to
platelet sonicate by forming more and larger colonies in soft
agar. The quantitation of this proliferative response showed
substantial increases in total cell numbers within colonies for
cells from cell strains and biopsies. The results demonstrate the
ability of an acid-labile platelet sonicate activity to support the
expression of the transformed phenotype of human metastatic
melanoma.
MATERIALS AND METHODS
Maintenance of NRK Fibroblasts. The NRK clone 49F cells were
generously provided by Dr. Harold Moses of the Mayo Clinic. These cells
were maintained in DMEM (GIBCO, Santa Clara, CA) supplemented with
10% heat-inactivated FBS (GIBCO), glutamine (0.8 ^g/ml; GIBCO), and
gentamicin 10 ng/ml; Irvine Scientific, Santa Ana, CA).
Establishment and Culture of Melanoma Cell Strains and Line. Cell
strains and the one cell line from human metastatic malignant melanoma
were established from patient tumor biopsy samples that had been
successfully cloned in agar, as described previously (5). The cells were
maintained in monolayer in RPM11640 (GIBCO) supplemented with 10%
FBS, glutamine (0.8 Mg/ml), and gentamicin (10 ng/ml). All experiments
that assessed colony formation in soft agar from cell strains and the cell
line were done on cells from passages 1 to 7.
Soft Agar Assay. Growth of human malignant melanoma in soft agar
has been described (14). The procedure used in this study involved these
modifications. Cells were plated in RPMI 1640 supplemented with 10%
FBS, glutamine (0.8 Â¿ig/ml),and gentamicin (10 Mg/ml). In experiments
utilizing suboptimal growth conditions for M1RW5 cells, the plating
medium was either RPMI plus 1% FBS or DMEM (GIBCO) plus 1% BSA
(Sigma). Dose-range curves for optimal cell concentration and colony
formation were done for all cell cultures and biopsies (15). Cell concen
trations chosen for plating were those in the midrange of concentrations
showing a linear relationship between number of cells plated and number
of colonies formed. Confluent flasks of melanoma cells were harvested
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using 0.25% trypsin (GIBCO). Melanoma cell strains C822, C8161,
C832C, and C8157 were plated in the overlayer at cell concentration of
10,000 cells/plate. The cell line M1RW5 was plated at 5,000 cells/plate.
Cells from cryopreserved or fresh patient biopsy sampleswere plated at
50,000 to 300,000 cells/plate in Ham's F-10 medium(GIBCO).No other
additives were used in the patient sampleplating medium.The NRK 49F
cellswere plated at 5,000 cells/plate in DMEM with 10% FBS.The plates
were incubated in a sealed, humidified modular incubator chamber
(Phillips-Rothenberg,Inc., Del Mar, CA) gassed with a mixture of 95%
air and 5% CO2, and placed in a 37Â°Cincubator. The colonies from
short-term melanoma cell strains and melanoma biopsy cells were
counted on day 14, while the M1RW5 and NRK colonies were counted
on days 7 to 9. The colonieswere counted and grouped into size classes
based on colony diameter, using an optical image analyzer (Omnicon
FAS II; Bausch and Lomb, New York, NY) (25). As a control for cellular
aggregation, day 0 counts of M1RW5 and biopsy 8442 cells were
performed in the presence or absence of platelet sonicate. We routinely
measured both the number of colonies (cloning efficiency) and the
number of cells in colonies (proliferativecapacity).
Quantitationof Cell NumberswithinColonies.Colonieswere sized
and counted on the OmniconFAS II, and cell diametersof individualcells
were measured by inspection under an inverted microscope. These
values were used in the following formula to calculate the number of
cells within coloniesof specific size classesas described previously(17).
2.40 (colony diameter)2378
No. of cells/colony = ^~^T ^^iCell diameter2804
See Table 1 for the number of cells contained within colonies of a
particular diameter. The number of cells within each colony size class
was multiplied by the number of colonies in that size class to generate
the total number of cells per size class. Adding all these numbers results
in the total number of cells in colonies per plate.
PlateletSonication.Anoutdatedunitofhumanplateletswasobtained
from the University of Arizona Health Sciences Center Hospital Blood
Bank. The platelets were diluted 1:2 in double-distilledwater and soni
cated at low amplitude for 30 s using an Ultratip Microprobe Sonicator
(New Brunswick Scientific, New Brunswick, NJ).Lysate was centrifuged
at 5000 x g for 15 min and the supernatant was aliquoted into 1-ml
samplesand lyophilized.Sampleswere rehydrated with 1 ml of PBS and
sterilized by passage through a Millipore0.22-Mmfilter prior to use in the
colony-forming assay. Platelet sonicate was added to the soft agar
overlayersover a concentration range of total protein.
Protein Determination.Proteinconcentrationswere determinedby
using Bio-Rad Protein Assay (Bio-Rad Laboratories, Richmond, CA).
This assay is based on the Bradford method utilizingCoomassieBrilliant
Blue G-250 to assess protein binding.
Physical Treatment of Platelet Sonicate. A lyophilizedsampleof
platelet sonicate was hydrated with 0.1 M NH4HCO3in PBS containing
0.065 M DTT (18).The sample was lyophilized in 4 ml of PBS after a 1-
h incubation at room temperature. Another sampleof sonicate was also
subjected to 5% trypsin digestion for 24 h at 37Â°C.After eachtreatment,
the sonicate was evaluated for the ability to stimulate soft agar growth
of M1RW5 cells in 1% FBS-RPMI or 1% BSA-DMEM. Acid stability of
the activity was assessed by treatment of the platelet sonicate with 4
Table 1
Number of melanomacells contained within specific sized colonies
No. of cells in colony
with following diameter
Cell strain
orline 42-50 >im 51-60^m 61-72>im 73-86 ion 86-104 ^m
mw HCI at 4Â°Cfor 24 h. Acid-treated and nontreated samples were
assayed in 1% BSA-DMEMwith M1RW5 cells. NRK cells were assayed
in 10% BSA-DMEM,and they served as a positive control for acid-stable
TGF activity.
Effects of OtherGrowthFactors. Inadditionto plateletsonicate,the
M1RW5 cells were assayed for growth factor requirements in soft agar.
The following growth factors were added individuallyto 1% FBS-RPMI:
EGF; FGF; NGF; PDGF (Collaborative Research, Inc., Lexington, MA);
transferrin (Sigma ChemicalCo., St. Louis, MO); or insulin (Eli Lilly and
Co., Indianapolis,IN). For growth factor evaluations in 1% BSA-DMEM,
the following growth factors were added alone or in combination: TGF-
a (R. Derynck, M. Winkler, Genentech, Inc., San Francisco, CA); TGF-/3
(Dr. Harold Moses, Mayo Clinic, Rochester, MN); PDGF;and EGF.
RESULTS
Cloning Efficiencies. The growth properties of the Å“ilstrains
(C8157, C8161, and C822) and the cell lines (NRK 49F and
M1RW5) were evaluated prior to assessment of responses to
platelet sonicate. Two of these, the NRK fibroblasts and the
C822 melanoma cells, had poor growth capabilities in soft agar
with cloning efficiencies for colonies >60 /Â¿min diameter of 0
and 0.6%, respectively. In contrast, under identical growth con
ditions (10% FBS), the other melanoma cells displayed high
cloning efficiencies in soft agar for colonies >60 /im in diameter.
The short-term cell strains had an average cloning efficiency of
8%, and the M1RW5 long-term cell line cloned with an average
efficiency of 18%. The responses of cells from melanoma biop
sies, the NRK 49F fibroblasts, and the C822 cells to platelet
sonicate were therefore evaluated in 10% FBS-containing me
dium. The other melanoma cells were assayed in 1% FBS-
containing medium which resulted in the decreased cloning
efficiency of these cells and allowed for observation of growth
potentiation after platelet sonicate addition.
Effect of Platelet Sonicate on Growth of NRK 49F Cells in
Soft Agar in 10% FBS DMEM. The NRK cells responded to
sonicated platelets by forming colonies in soft agar (Chart 1).
Maximal stimulation of all colony sizes examined occurred at the
IOOO-
M1RW5C8161C8157C832CC822171243241326196536203929101563160451558547947024013273
0 0.08 0.0 I.6
CONCENTRATION OF PLATELET SONICATE (mg/ml)
4.0
Chart 1. Effects of platelet sonicate on NRK fibroblast colony formation in soft
agar. Cells were plated in 10% FBS-DMEM medium over a platelet concentration
range. , colonies >60 Â¡onin diameter; , colonies >124 ^m in diameter;
oars, SD.
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4-mg/ml level of platelet sonicate protein, but activity was ap
parent at 800 Â¿tg/mlfor colonies greater than 60 firn in diameter.
Control plates on day 0 had 20 Â±6 counts and platelet sonicate-
treated plates had 32 Â±4 counts. These counts represented
0.6% of the total cells plated and 1% of the total colonies formed.
These counts confirmed that the platelet sonicate was not caus
ing a large number of aggregates to form which could subse
quently be erroneously counted as colonies.
Effect of Platelet Sonicate on Melanoma Colony-forming
Cell Growth in Soft Agar. The responses of the four melanoma
cell strains and one melanoma cell line are shown in Chart 2.
The culture conditions were identical for all cells except that the
C822 cells were assayed in medium supplemented with 10%
FBS instead of 1% as for the others. All the melanoma cells
responded to the platelet sonicate in a dose-dependent manner
with half-maximal stimulation seen protein levels between 160
and 800 fig/ml. The cells assayed in 1% FBS were unable to
form colonies greater than 60 Â¿imin diameter, yet the addition
of platelet sonicate resulted in formation of at least 600 colonies
greater than 60 urn for all four cell lines. For the M1RW5 cells,
the counts on day 0 were 24 Â±6 for nontreated plates and 14
Â±2 for sonicate-treated plates which represented 0.4% of total
cells plated and 0.8% of total colonies formed.
Cells from ten melanoma biopsies were assayed for responses
to platelets in 10% FBS-containing medium. Six of the ten patient
samples did not grow, with or without platelets. Table 2 shows
the data for cells from those four melanoma biopsies which grew
colonies over 60 fÂ¿min diameter without platelet addition. The
_.OI 0.080.1 0.16 0.4 0.81.0 1.6
CONCENTRATION OF PLATELET SONICATE (mj/ml)
Chart 2. Effects of platelet sonicate on human metastatic melanoma colony-
forming cells in soft agar. Platelet protein was added to overlayer with cells in 1%
FBS-RPMI medium ( ) or 10% FBS-RPMI medium ( ). â€¢M1RW5; â€¢,
C8161; A, C832C; O, C8157; D, C822; oars, SE.
Table 2
Responsesof cells from melanomabiopsies to platelet sonicate (400 ng/ml) for
colonies >60 tÂ¡min diameter
Patient8240a
8414e
8423e
8442sNo.
ofcoloniesControl
Plusplatelets166
+ 60" 1160 Â±98
50 Â±2 452 Â±18
358 Â±28 674 Â±54
988 Â±146 1666 + 240%of
increase
over
control699
904
188
169
presence of 400 ug of platelet protein/ml increased the number
of colonies by 100 to 900%. On day 0, the control and sonicate-
treated plates for biopsy 8442 had the same number of counts
(24 Â±6). These counts represented 0.05% of the total cells
plated and 1.4% of the total colonies formed and therefore
demonstrate that the sonicate did not induce aggregate forma
tion prior to plating in soft agar where migration and aggregation
are inhibited (27).
Effect of Platelet Sonicate on Cellular Proliferation of Mel
anoma Colony-forming Cells. In order to examine the platelet
effects on proliferation, we measured different size classes of
colonies and calculated the number of cells within colonies of
different sizes to enumerate the total number of cells contained
in all colonies formed and thus total cellular proliferation. Table
3 summarizes the data for the melanoma cell cultures with regard
to number of colonies formed and number of cells within colonies
>42 urn in diameter in the control and treated plates. The three
cell strains (C8157, C8161, and C832C) and one cell line
(M1RW5) assayed in 1% FBS had approximately 1000 total cells
within all the colonies. The addition of platelet sonicate increased
the total number of cells within all colonies to over 26,000 for
M1RW5, 22,900 for C8161, 39,600 for C832C, and 56,500 for
C8157. The other cell strain that was evaluated in 10% FBS,
C822, increased total cell numbers within colonies from 4,300 to
17,500 after platelet treatment.
Characteristics of Platelet Sonicate by Physical Treatment.
Table 4 shows the sensitivity of the platelet sonicate to treatment
with DTT, trypsin, and acid. DTT treatment reduced the stimu
lation to less than 3% of growth achieved with platelet sonicate
treatment, and trypsin treatment resulted in reduction of stimu
lation to 4% of platelet sonicate-treated plates. This sensitivity
to DTT and trypsin suggests that the sonicate activity is due to
a protein. The acid treatment of the platelet sonicate resulted in
the loss of stimulatory activity for human melanoma, while the
activity for NRK fibroblasts was maintained and even slightly
enhanced (Table 4). Acid treatment destroyed 95% of melanoma-
Table3
Totalcellular proliferation calculated for humanmelanomacells in the presence
and absenceof platelet sonicate
* Cryopreserved sample.
6 Mean Â±SE.
c Fresh tumor sample.
Cell TotalcoloniesCell
line Cells diameter Growth >42Â¡anor
strainplated/dishM1RW5
5,000C8161
10,000C832C
10,000C8157
10,000C822
10,000"The
number ofcellsdescribed
previously (15).(urn)
condition19.8
1%FBS1%
FBS +platelets(1
mg/ml)10%
FBS22
1%FBS1%
FBS +platelets(1
.6mg/ml)10%
FBS17.8
1%FBS1%
FBS +platelets(1.6
mg/ml)10%
FBS14.2
1%FBS1%
FBS +platelets(1.6
mg/ml)10%
FBS21.6
10%FBS10%
FBS +platelets(1
mg/ml)diameter1221,5561,9481681,2681,448501,0321,942147521,0824881,242Totalcells*incolonies1,02826,33145,9321,16422,90124,56364539,62587,50351356,52899,0184,35617,540within
specific colony size classes was calculatedasAddition
of the number of cells from eachsizeclassresults
in total number of cells per plate.
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Table 4
Characterizationof platelet sonicate by physical treatments
Colonies
Table6
Effects of known growth factors from humanplatelets
% of control growth"
Cell lineTr atm ntM1RW5
DTTTrypsinAcidNRK
AcidGrowth
condition10%
FBS-RPMI control
1% FBS-RPMI control
1% FBS-RPMI + sonicate
1% FBS-RPMI + DTT-treated
sonicate10%
FBS-DMEM control
1% BSA-DMEM control
1% BSA-DMEM + sonicate
1% BSA-DMEM + trypsin-treated
sonicate10%
FBS-DMEM control
1% BSA-DMEM control
1% BSA-DMEM + sonicate
1% BSA-DMEM + acid-treated
sonicate10%
FBS-DMEM control
10% FBS-DMEM + sonicate
10% FBS-DMEM + acid-treated
sonicatein
diameter2840
Â±114"
210 Â±12
2076 Â±42
56 Â±101132
Â±44
4Â±1
330 Â±10
14Â±21594
Â±77
24 Â±10
414 + 24
22Â±10704
Â±38
1566 Â±118
2604 Â±38
" Mean Â±SE.
Table 5
M1RW5cellular responses to growth factors in 1%FBS-containingRPMI
Factor"EGF
(100 ng/ml)
PDGF(1 unit/ml)
FGF (100 ng/ml)
NGF(100 ng/ml)
Insulin (100 ng/ml)
Transferrin (500 ^g/ml)%
of Control
growth
(colonies> 60 ^m
in diameter)107
150
140
91
142
200
a Each growth factor was plated in the upper layer of soft agar with the M1RW5
cells.
stimulatory activity but resulted in a 370% increase in colony
formation by NRK fibroblasts. This indicates that the stimulation
of melanoma colony-forming cells is not an effect of acid-stable
activities from human platelets such as PDGF, EGF, and TGF-0.
Growth Factor Responses. In order to evaluate growth factor
requirements for the expression of the anchorage-independent
phenotype in human melanoma, the M1RW5 cells were plated
in 1% FBS-RPMI in the presence of known growth factors. The
concentration of each growth factor that gave the greatest
stimulation of M1RW5 cellular growth in soft agar was derived
from dose-response curves with each growth factor. Table 5
illustrates the limited responses of human melanoma to the
purified growth factors tested.
The results of the more detailed studies of melanoma cellular
responses to specific growth factors present in human platelets
are shown in Table 6. These results were obtained from the
concentration of each growth factor that gave the greatest
stimulation of M1RW5 growth. For M1RW5 cells, the combina
tion of PDGF, TGF-a, and TGF-/9 stimulated only 27% of the
growth promotion obtained with the platelet sonicate.
In contrast, the NRK cells responded to these growth factors
as described previously (3), in that maximal colony formation
was observed with the combination of the three proteins PDGF,
TGF-a, and TGF-0. These results suggest that the melanoma-
FactorPlatelet
sonicate (18 ng/ml)
PDGF (1 unit/ml)
EGF (1 ng/ml)
TGF-a (5 ng/ml)
TGF-0(5no,/ml)
TGF-a + TGF-/3
TGF-a + TGF-/3 + PDGF
EGF + TGF-0 + PDGFM1RW5100
20
2
2
2
11
27
7NRK100
56
45
42
0.8
115
179
138
* For each cell line, the control represents optimal growth in the presence of the
platelet sonicate. The M1RW5 cells had 602 colonies in 1% BSA-DMEM plus
sonicate, and the NRK cells had 1566 colonies in 10% FBS-DMEM plus sonicate.
stimulatory activity present in human platelets is not due to acid-
stable growth factors such as PDGF, TGF-0, TGF-a, or EGF.
DISCUSSION
Human metastatic malignant melanoma cells from patient biop
sies, cell strains, and a cell line responded to a sonicated human
platelet preparation by forming more and larger colonies than did
nontreated controls. Cells from biopsies which did not respond
to platelets had no growth on the control plates, which suggests
that cells must be capable of at least some colony formation in
order to respond to platelet factors. The clonogenic cells that
grew were able to go through extensive proliferation upon the
addition of platelet sonicate to the system. A comparison of the
total number of cells in colonies in control and platelet-treated
cultures reflects this tremendous growth increase (Table 3). This
stimulation represents a proliferative response to the platelet
sonicate, because day 0 counts revealed no aggregate induction
by the sonicate. The results shown here indicate that factors
present in platelet sonicate stimulated the clonogenic cells to
express the transformed phenotype, even in the presence of
reduced FBS. The previous work of Cowan and Graham (7)
suggested that a variety of human tumors were capable of
responding to platelet lysate, but their method of manually count
ing formaldehyde-stained colonies did not allow for a precise
measure of proliferative events stimulated by platelet treatment.
Our work confirms the responsiveness of melanoma tumor cells
to human platelets and also quantitates this proliferative re
sponse for human metastatic malignant melanoma colony-form
ing cells. The results demonstrate that factors within platelets
stimulated increases in the cloning efficiency and proliferative
capacity of human melanoma colony-forming cells.
Serum contains a complex mixture of hormones and growth
factors which stimulate growth (4, 19). Growth factors are non-
nutritive substances that control proliferation in a regulative
manner without participating directly in biosynthesis, metabo
lism, or catalysis (9). Because C822 cells exhibited low cloning
efficiency in soft agar in 10% FBS-supplemented medium, they
must have a greater requirement for growth-regulatory molecules
than those which can be supplied by 10% FBS. The growth
factors contained in platelets may provide a proliferation signal
for C822 cells beyond those molecules supplied by 10% FBS.
This point is well illustrated by increased proliferation of these
cells with the addition of platelet sonicate to 10% FBS-containing
medium (Chart 2).
In contrast to C822 cells, the cells from other melanoma strains
were capable of responding to the growth stimuli supplied by
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10% FBS, as shown by their relatively high cloning efficiencies
in soft agar. For responsive cells, the growth factors present in
10% FBS could interfere in assays for growth-regulatory mole
cules; therefore the growth-promoting capacity of serum was
largely obviated by reducing the FBS concentration to 1% for
studies using cells from C8157, C8161, C832C, and M1RW5.
This approach allowed for evaluation of substances that regu
lated colony-forming growth in soft agar that would otherwise
be masked by the growth-promoting substances present in
serum (4, 6, 23). The reduction to 1% FBS does not represent
nutritional deprivation, because the addition of the platelet soni
cate resulted in an average of 73% of the growth observed with
10% FBS (Table 4).
The response of melanoma cells to platelet sonicate was
observed over reasonably small additions of protein to the sys
tem. The FBS lot used in these studies contained approximately
4.2 mg of total protein/ml at the 10% concentration. In assays
utilizing 1% FBS, the addition of platelet sonicate at the highest
concentration examined resulted in a total protein concentration
of 2 mg/ml, and clear responses were observed at a total protein
concentration of 520 /*g/ml for the M1RW5 cell line. In addition,
a dose-response curve for M1RW5 using bovine serum albumin
up to a concentration of 2.5% gave no stimulation of colony
formation (data not shown). These results suggest that the
growth stimulation observed with this platelet sonicate was not
merely a nonspecific protein effect, but rather specific activity of
protein(s) which play a role in expression of the transformed
phenotype in soft agar.
None of the growth factors assayed individually (EGF, PDGF,
NGF, FGF, insulin, or transferrin) increased the soft agar prolif
eration of melanoma cells to the same extent as did the platelet
sonicate factor(s). The greatest stimulation on proliferation of
M1RW5 cells in 1% FBS plating medium was 200% over control
after plating with a high concentration of transferrin, while the
platelet sonicate stimulated colony formation to 1200% over 1%
control growth. This implies that the platelet sonicate contained
growth factor activity which was not substituted by the purified
growth factors tested. Studies of melanoma cellular responses
to characterized growth factors from human platelets also re
vealed that these proteins (PDGF, EGF, or TGF-a-like and TGF-
0) do not play a significant role in the expression of the trans
formed phenotype for human melanoma.
In addition, physical treatment of the platelet sonicate with
DTT, trypsin, or acid resulted in decreased activity. This loss of
activity with acid treatment is different from other characterized
growth factor activities from human platelets. EGF, PDGF, and
TGFs have all been shown to be stable under acidic conditions
(2, 21, 22, 26). The acid sensitivity of the melanoma-stimulatory
activity coupled with the inability of acid-stable activities such as
PDGF, EGF, TGF-a, and TGF-/3 (alone or in combination) to
stimulate melanoma colony formation in soft agar indicate that
human platelets contain a neutral protein which can drive mela
noma cells to express their transformed phenotype, and this
factor is different from activities previously characterized from
human platelets. Studies are in progress to isolate and charac
terize this growth factor activity for human melanoma.
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